Kamada Ltd Revenue Growth Rates (KMDA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Kamada Ltd   (NASDAQ: KMDA)
 

KMDA's Revenue Growth by Quarter and Year

Kamada Ltd 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KMDA Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 44.68
3rd Quarter September 47.01
2nd Quarter June 44.75
1st Quarter March 44.02
FY 180.46

KMDAs Annual Revenue
Kamada Ltd 's Revenue in the fiscal year 2025 $ 180.46 millions
Kamada Ltd 's Revenue in the fiscal year 2024 $ 160.95 millions
Kamada Ltd 's Revenue in the fiscal year 2023 $ 142.52 millions
Kamada Ltd 's Revenue in the fiscal year 2022 $ 129.34 millions
Kamada Ltd 's Revenue in the fiscal year 2021 $ 103.64 millions




KMDA Revenue fourth quarter 2025 Y/Y Growth Comment
Kamada Ltd reported Revenue increase of 14.53% year on year in the fourth quarter 2025, to $ 44.68 millions, this is lower than Kamada Ltd 's recent average Revenue surge of 13367.28%.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 27 other companies have achieved higher Revenue growth. While Kamada Ltd ' s Revenue growth of 14.53% ranks overall at the positon no. 150 in the fourth quarter 2025.


KMDA Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 14.53 % -72.63 % 10.19 % 24.8 %
3rd Quarter September 12.63 % 10.04 % 17.72 % 39.9 %
2nd Quarter June 5.37 % 13.43 % 58.71 % -2.68 %
1st Quarter March 16.64 % 22.89 % 9.33 % -
FY   12.11 % -35.25 % 16.58 % -

Financial Statements
Kamada Ltd 's fourth quarter 2025 Revenue $ 44.68 millions KMDA's Income Statement
Kamada Ltd 's fourth quarter 2024 Revenue $ 39.01 millions Quarterly KMDA's Income Statement


KMDA Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December -4.96 % -6.54 % 275.74 % 301.43 %
3rd Quarter September 5.05 % -1.72 % 1.31 % 36.58 %
2nd Quarter June 1.66 % 12.53 % 21.91 % -16.02 %
1st Quarter March 12.84 % -73.52 % -76.26 % -72.9 %
FY (Year on Year)   12.11 % -35.25 % 16.58 % -


Back to KMDA Growth rate Comparisons >> Back to KMDA Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #28
Healthcare Sector #50
Overall #150

Revenue Y/Y Growth Statistics
High Average Low
122778.54 % 13367.28 % -99.89 %
(Dec 31 2022)   (Dec 31 2021)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #28
Healthcare Sector #50
Overall #150
Revenue Y/Y Growth Statistics
High Average Low
122778.54 % 13367.28 % -99.89 %
(Dec 31 2022)   (Dec 31 2021)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Kamada Ltd 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
401361.96 % 24944.34 % -100 %
(Dec 31 2022)  


KMDA's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2025 Kamada Ltd disclosed fall in Revenue from the third quarter by -4.96% to $ 44.68 millions, from $ 47.01 millions achived in the previous reporting period.

But that's not important problem, as Kamada Ltd 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Revenue quarter on quarter growth. While Kamada Ltd 's Revenue growth quarter on quarter, overall rank is 100.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #38
Overall #100
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #38
Overall #100
Revenue Q/Q Growth Statistics
High Average Low
401361.96 % 24944.34 % -100 %
(Dec 31 2022)  


KMDA's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2025 Kamada Ltd disclosed fall in Revenue from the third quarter by -4.96% to $ 44.68 millions, from $ 47.01 millions achived in the previous reporting period.

But that's not important problem, as Kamada Ltd 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Revenue quarter on quarter growth. While Kamada Ltd 's Revenue growth quarter on quarter, overall rank is 100.


Kamada Ltd 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 180.46 $ 160.95 $ 142.52 $ 129.34 $ 103.64
Y / Y Revenue Growth (TTM) 12.12 % 12.93 % 10.19 % 24.79 % -22.22 %
Year on Year Revenue Growth Overall Ranking # 2560 # 3452 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 12.12 % 12.93 % 10.19 % 24.79 % -22.22 %
Seq. Revenue Growth (TTM) Overall Ranking # 2560 # 1846 # 0 # 0 # 0


Cumulative Revenue growth Comment
Assuming the Kamada Ltd 's fiscal year would have ended in Dec 31 2025, Kamada Ltd would have reprted above average annual Revenue increase of 12.12% year on year, of $ 180 millions.
This marks a slow-down of the companys growth trends and from the 12.93% rise in Dec 31 2024.

In the Healthcare sector 324 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2560, from total ranking in previous quarter at 3452.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 112
Healthcare Sector # 325
Overall # 2560

Revenue TTM Y/Y Growth Statistics
High Average Low
24.79 %
 4.38 %
-22.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 112
Sector # 325
S&P 500 # 2560
Cumulative Revenue growth Comment
Assuming the Kamada Ltd 's fiscal year would have ended in Dec 31 2025, Kamada Ltd would have reprted above average annual Revenue increase of 12.12% year on year, of $ 180 millions.
This marks a slow-down of the companys growth trends and from the 12.93% rise in Dec 31 2024.

In the Healthcare sector 324 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2560, from total ranking in previous quarter at 3452.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 112
Healthcare Sector # 325
Overall # 2560

Revenue TTM Y/Y Growth Statistics
High Average Low
24.79 %
4.38 %
-22.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 112
Sector # 325
S&P 500 # 2560




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
KMDA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Concord Medical Services Holdings Ltd25.19%$ 25.189 millions
Caredx Inc 25.19%$ 25.187 millions
Addus Homecare Corp25.17%$ 25.168 millions
Tela Bio Inc 24.88%$ 24.883 millions
Emmaus Life Sciences Inc 24.62%$ 24.620 millions
Invivyd Inc 24.51%$ 24.508 millions
Immunocore Holdings Plc24.30%$ 24.302 millions
Akebia Therapeutics Inc 23.93%$ 23.926 millions
Amicus Therapeutics inc 23.72%$ 23.717 millions
Vericel Corporation23.27%$ 23.273 millions
Koru Medical Systems Inc 23.27%$ 23.270 millions
Exact Sciences Corporation23.12%$ 23.122 millions
Precipio inc 22.92%$ 22.917 millions
Penumbra Inc22.14%$ 22.144 millions
Sonoma Pharmaceuticals Inc 22.03%$ 22.026 millions
Quanterix Corporation21.76%$ 21.756 millions
Innoviva Inc 21.66%$ 21.663 millions
Tactile Systems Technology Inc 21.58%$ 21.578 millions
Harmony Biosciences Holdings inc 21.49%$ 21.487 millions
Supernus Pharmaceuticals inc 21.48%$ 21.482 millions
Axogen inc 21.25%$ 21.253 millions
Rigel Pharmaceuticals Inc21.19%$ 21.192 millions
Phibro Animal Health Corporation20.98%$ 20.975 millions
Ensign Group Inc20.17%$ 20.170 millions
Artivion Inc 19.94%$ 19.940 millions
Neuropace Inc 19.79%$ 19.785 millions
Alvotech19.70%$ 19.701 millions
Alphatec Holdings Inc 19.54%$ 19.544 millions
Lifeloc Technologies Inc 19.00%$ 19.003 millions
Intuitive Surgical Inc 18.82%$ 18.817 millions


About Kamada Ltd Revenue Growth Rates (KMDA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Kamada Ltd (CIK 1567529).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-025934
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Kamada Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.